We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Dramatic Growth Predicted for Global POC Testing Segment

By LabMedica International staff writers
Posted on 19 Oct 2009
Print article
The global point-of-care (POC) testing market will experience striking growth from US$12.8 billion in 2008 to $17.8 billion by 2014 according to a new report.

Distributed by Life Science Intelligence (LSI; Huntington Beach, CA, USA), the report provides a global analysis of the patients, procedures, technologies, and companies driving growth and innovation in the POC testing market. It is divided into three main segments: hospital bedside testing products; home and self-testing products; and physician's office lab products.

Each of these areas is divided by product and geography with detailed share-by-supplier information. Various factors contributing to the expected growth include: the demands of physicians for more efficient approaches to the delivery of care; demands for faster access to diagnostic test results to optimize patient outcomes in emergency and critical care settings; the development of advanced analytical technologies, including high-sensitivity assays suitable for POC use, as well as microfluidics technologies that enable highly sophisticated assays to be performed at the bedside by nonlaboratory personnel, with accuracy equivalent to that achieved in the central laboratory; and advanced computer and communications technologies that allow POC testing to be managed as effectively as tests performed in the central lab.

The report is based on a study that included more than 200 interviews with pathologists and laboratory directors; investigators and technical experts; and company presidents, marketing executives, and business development executives.

LSI delivers market data and competitive intelligence to medical technology executives, entrepreneurs, and investors. LSI produces the EMT (Emerging Medical Technologies) Database, EMT (Emerging Medical Technologies) Spotlight events, medtech market reports, and provides global custom research services.

Related Links:

Life Science Intelligence



New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Automated Blood Typing System
IH-500 NEXT
New
Chemistry Analyzer
MS100
New
Lab Sample Rotator
H5600 Revolver

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.